From: Status of adjuvant endocrine therapy for breast cancer
Study | Number | Population (treatment received pre-enrollment) | Arms at random assignment | Study number |
---|---|---|---|---|
MA.17R | 1,918 | Prior 4.5-6 years of AI, with or without prior Ta | L (5 years) versus placebo (5 years) | NCT00754845 |
Completed AI ≤2 years prior random assignment | ||||
SALSA | 3,486 | Any endocrine therapy (5 years) | A (5 years) versus A (2 years) | NCT00295620 |
LEAD | 4,050 | T (4-6 years) | L (5 years) versus L (2-3 years) | NCT01064635 |
DATA | 1,900 | T (2-3 years) | A (6 years) versus A (3 years) | NCT00301457 |
NSABP-B42 | 3,966 | AI or T→AIb (to 5 years) | L (5 years) versus placebo (5 years) | NCT00382070 |
SOLE | 4,800 | Any endocrine therapyc (5 years) | L (5 years) versus intermittentd L (5 years) | NCT00553410 |